Main Conclusion: Mazdutide (IBI362) is an investigational dual GLP-1 and glucagon receptor agonist that delivers substantial body weight reduction, robust glycemic control, and pronounced hepatic lipid clearance by synergizing appetite suppression with elevated metabolic energy expenditure.
Supporting Reasons
- Balanced Dual-Agonist Pharmacodynamics: Its engineered oxyntomodulin-based structure co-activates GLP-1R and GCGR to counteract hyperphagia while simultaneously stimulating hepatic lipid turnover and thermogenesis.
- Demonstrated Human Clinical Efficacy: Multiple randomized controlled Phase 2 and Phase 3 trials confirm dose-dependent, double-digit percentage body weight loss and substantial HbA1c reductions in metabolic cohorts.
- Profound Hepatic and Cardiometabolic Remodeling: Beyond weight loss, direct hepatic glucagon agonism drives marked reductions in liver fat content and circulating atherogenic lipids, supporting its therapeutic role in metabolic dysfunction-associated steatotic liver disease (MASLD).
Detailed Evidence Base
Reason 1: Balanced Dual-Agonist Pharmacodynamics
In-Vitro Evidence
- Receptor Binding & cAMP Generation: In-vitro functional assays using recombinant cell lines express both human GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR), demonstrating that mazdutide acts as a full dual agonist, inducing cyclic adenosine monophosphate (cAMP) accumulation downstream of both receptors with balanced nanomolar potency.
- Peptide Stability: Chemical modification via a C20 fatty diacid side chain provides high-affinity reversible binding to human serum albumin, resisting enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase (NEP).
Animal Evidence
- Energy Expenditure: Indirect calorimetry studies in diet-induced obese (DIO) mice revealed that mazdutide increased resting energy expenditure (REE) and oxygen consumption relative to selective GLP-1 mono-agonists, confirming glucagon-mediated metabolic activation.
- Food Intake Regulation: Murine feeding assays demonstrated significant acute and chronic hypophagia mediated through central nervous system GLP-1R activation in the hypothalamus and hindbrain.
Hypotheses & Mechanistic Models
- Researchers hypothesize that the simultaneous activation of GLP-1R suppresses the potentially diabetogenic hepatic glycogenolysis normally triggered by uninhibited glucagon receptor activation, achieving metabolic harmony.
Reason 2: Demonstrated Human Clinical Efficacy
Human Clinical Evidence
- Phase 2 Obesity Trials: In a randomized, double-blind, placebo-controlled Phase 2 trial in Chinese adults with overweight or obesity, mazdutide (up to 9 mg weekly) induced mean body weight reductions of up to 15.4% at 24 weeks compared to placebo.
- Phase 3 GLORY-1 Trial: Top-line data from the 48-week Phase 3 registration trial (GLORY-1) in adults with overweight or obesity confirmed that both 4 mg and 6 mg doses met primary endpoints, showing mean weight loss exceeding 14% alongside significant reductions in waist circumference and systolic blood pressure.
- Phase 2/3 Glycemic Trials (DREAMS-1 & DREAMS-2): In patients with type 2 diabetes, mazdutide demonstrated significant HbA1c reductions (up to -1.8% to -2.15%) from baseline, with high proportions of subjects achieving normoglycemia without increased risk of severe hypoglycemia.
- Safety and Tolerability Profile: Clinical data indicate a safety profile consistent with the incretin-based class; the most frequent adverse events are mild-to-moderate gastrointestinal disturbances (nausea, diarrhea, vomiting) that predominantly occur during dose escalation.
Anecdotal Claims
- Anecdotal user reports from research forums often claim immediate appetite shutdown and heightened perceived warmth; however, such claims remain uncontrolled, non-peer-reviewed observations and should not replace clinical pharmacokinetic datasets.
Reason 3: Profound Hepatic and Cardiometabolic Remodeling
Human Clinical Evidence
- Liver Fat Content (LFC): In clinical trials utilizing magnetic resonance imaging-proton density fat fraction (MRI-PDFF), mazdutide administration resulted in relative liver fat reductions of up to 70–80%, with a high proportion of patients achieving complete resolution of hepatic steatosis (LFC < 5%).
- Lipid Profiles: Clinical cohorts exhibited robust reductions in total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), and serum uric acid levels, outperforming historical benchmarks of selective GLP-1 mono-agonists.
Animal Evidence
- Hepatic Histopathology: Preclinical MASLD/MASH rodent models treated with mazdutide showed marked reductions in hepatic macrovesicular steatosis, ballooning degeneration, and inflammatory biomarker expression (TNF-α, MCP-1) alongside enhanced hepatic β-oxidation.
Hypotheses
- Investigators hypothesize that the direct activation of hepatic GCGR upregulates mitochondrial carnitine palmitoyltransferase-1 (CPT-1), directly accelerating intrahepatic fatty acid oxidation independent of caloric deficit.